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The prevalence of gout is increasing with increased life expectancy. Approximately half of the patients with gout have some degree
of renal impairment. If both conditions persistently coexist, and in severe tophaceous gout, in particular, treatment has been
diﬃcult. We here report on the case of an 87-year-old woman, who had been suﬀering from recurrent gouty arthritis over 4 years.
Monthly polyarthritis attacks were accompanied by subcutaneous tophi. Serum uric acid levels were constantly above 600µmol/L
(10mg/dL).Allopurinol was no option because of intolerance, while benzbromarone was ineﬀective because of renal impairment.
Therefore, the novel xanthinoxidaseinhibitorfebuxostat wasstarted, achieving rapidcontrol of serum urate levels(<360µmol/L).
After initial worsening of inﬂammation in the ﬁrst weeks, gouty attacks stopped and all tophi resolved within the following 10
months.Renal function remained stable.
1.Introduction
Hyperuricemia, deﬁned as a serum urate concentration
higher than the limit of urate solubility (408µmol/L or
6.8mg/dL at 37◦C, pH 7.4), is common and can manifest
clinically as the urate crystal deposition disease, gout [1].
Gout is the most common arthritis in men, and its incidence
is rising with age [2]. If the underlying hyperuricemia
remains without suﬃcient therapy for years, chronic topha-
ceous gout may manifest. In addition to other comor-
bidities, such as hypertension, diabetes, and cardiovascular
disease, approximately every second patient with gout has
some degree of renal impairment, deﬁned by an estimated
glomerular ﬁltration rate (eGFR) of less than 90mL/min per
1.73m2 as per Cockroft-Gault equation corrected for ideal
body weight [3].
2.CasePresentation
An 87-year-old woman was seen at the rheumatology
because of chronic tophaceous gout. Monthly polyarticular
gout ﬂares aﬄicted both ﬁrst metatarsophalangeal joints, as
well as both wrists and multiple ﬁnger joints for approxi-
mately 4 years. The patient became bed-ridden, could not
perform simple, everyday tasks of self-care (e.g., washing,
dressing) and daily living (e.g., laundry, cooking), and
required help from her daughter.
Two years earlier, her general practitioner had appro-
priately started allopurinol. However, after 4 weeks, the
patient had developed an itching generalised exanthema,
so that allopurinol had to be stopped. Benzbromarone
was given at a dose of 50mg q.d. but had an insuﬃcient
eﬀect on serum uric acid levels, which still remained at
500µmol/L.During thelastyear, thepatienthadadditionally
developed multiple tophi located over the distal ﬁnger joints
and both metatarsophangeal joints. Her pre-existing renal
insuﬃciency had worsened (eGFR 30mL/min). Further
comorbidities of the patient included arterial hypertension,
noninsulin-dependent diabetes mellitus, and permanent
atrial ﬁbrillation.
On the ﬁrst admission to our department the patient
was sitting in a wheelchair, appeared depressive, and suﬀered2 Case Reports in Medicine
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Figure 1: Clinical presentation: Tophi over the right distal interphalangeal joint II. (a) Before therapy with febuxostat. (b) After 10 months
of therapy.
Figure 2: Radiograph of right hand showing the destructive char-
acter of recurrent crystal induced arthritis.
from severe pain (Visual analogue scale, VAS 8-9) and loss
of function of distal ﬁnger joints, wrists and feet. Physical
examination showed normal temperature, elevated blood
pressure160/80mmHgand anirregularpulseof80–90beats
per minute. Otherwise, heart and lungs were normal, as
were abdomen and the lumbar region. Joint examination
revealed swollen painful wrists and distal ﬁnger joints with
deformities and loss of mobility. Multiple subcutaneous
tophi were visible (Figure 1(a)). Radiographs of both hands
andfeetshowedtophaceousgoutanddestructionofmultiple
ﬁ n g e rj o i n t s( Figure 2). RBC, platelets, LFTs, LDH, protein-
electrophoresis, and TSH were unremarkable. Leukocytosis
(12.6GPt/L), elevated CRP (25mg/L), and serum urate
(717µmol/L) were consistent with chronic gout. Her serum-
creatinine (218µmol/L) and urea (25.2mmol/L) were in-
creased approximately threefold. The estimated glomeru-
lar ﬁltration rate (eGFR) was calculated at 30mL/min per
1.73m2.
In this elderly lady with chronic tophaceous gout, signif-
icant renal impairment, and other comorbidities, we started
urate lowering therapy with 80mg of febuxostat q.d. (lower
doses are not available in Germany). Concomitantly, pro-
phylactic medication for expected gout attacks was started
with 10mg of Prednisolon q.d., 0.5mg of colchicine e.o.d.
day, and low-dose ibuprofen as needed. The patient was
advised to carefully monitor daily ﬂuid intake and urinary
excretion. As early as one week after the ﬁrst administration
of febuxostat, serum urate level was reduced to 328µmol/L.
Not surprisingly, given this steep decline in serum urate, the
patient experienced another severe polyarticular gout ﬂare.
Tophi were visibly inﬂamed, and her eGFR decreased to
20mL/min. Under forced diuresis and analgesia including
narcotics, the situation stabilized within the next 4 weeks;
the eGFR improved to 30mL/min. After 5 months, the gouty
attacks have stopped and the tophi have started to resolve
(Figure 1(b)).Quality oflife improvedimpressingly (pain on
VAS2-3),andthepatientregained theabilitytowalkwithout
help for up to half an hour.
3.Discussion
Coexistence of chronic tophaceous gout and renal insuﬃ-
ciencyposesasigniﬁcanttherapeuticchallenge.Management
of chronic gout is targeted on lowering and maintainingCase Reports in Medicine 3
serum uric acid at subsaturating concentrations below
360µmol/L (6mg/dL) [4]. The two available pharmacolog-
ical targets of urate reduction are xanthin oxidase (XO)
inhibition and enhancement of urinary excretion with uri-
cosuric agents. However, uricosuric agents, such as benzbro-
marone and probenecid, have limited eﬀectiveness, and in
patients with impaired renal function in particular [5].
Therefore, for decades, the purine analogue XO inhibitor
urate has remained the mainstay of gout therapy [6].
Since oxipurinol, its (active) metabolite, is renally excreted,
allopurinol requires dose reduction in patients with renal
impairment [7]. Such lower doses often are not suﬃciently
eﬀective.In addition, allergic reactions to allopurinol are not
uncommon, and may be severe [8]. In these cases, the non-
purine xanthin oxidase inhibitor febuxostat represents an
alternative, because it is chemically distinct and metabolized
bytheliverandexcretedviabothliverandkidneys.Ingeneral
febuxostat is well tolerated in clinical trials [9, 10]. However,
some concerns were raised regarding elevation of liver
enzymes in 3–5%of patients. Becauseof a nonsigniﬁcant but
higher rate of death and cardiovascular events on febuxostat
compared to allopurinol 300 mg caution is recommended
in patients with ischaemic heart disease or severe congestive
heart failure [9,11].FebuxostatisapprovedinEurope,where
tablets of 80 and 120mg febuxostat are available.
Any urate lowering therapy should not be started during
an acute attack, since the dissolution of crystal deposits
increases the risk of gout attacks. For the same reason the
therapy should be started at a low-dose and titrated up
to the eﬀective dose to avoid the “crash”—reduction of
uric acid [12]. In our patient, eﬃcacy of febuxostat was
somewhat underestimated, and half of 80 mg daily might
havebeenamoreappropriatedose,withalesserriskofsevere
ﬂares. Appropriate prophylaxis against ﬂares poses the next
challenge. Both the use of colchicin and of nonsteroidal anti-
inﬂammatory drugs is severely restricted in such cases, given
signiﬁcant risks. Accordingly, combinations of steroids and
narcotics for short time often constitute the best available
option today [13].
4.Conclusion
We here present the case of an elderly lady with severe pol-
yarticular, tophaceous gout, coexistent renal insuﬃciency,
and allopurinol hypersensitivity. Under therapy with the
novel xanthin oxidase inhibitor febuxostat, serum uric acid
levels decreased to normal values. Over time, gout attacks
stopped and her tophi resolved. Renal function remained
stable.
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